Zhen Han

🧬🔍 SCOTCH: Single-Cell Omics for Transcriptome CHaracterization 🧫📊 Presented in a recent bioRxiv article by Zhuoran Xu, Hui-Qi Qu, Joe Chan, Charlly Kao, Hakon Hakonarson, and Kai Wang. SCOTCH uses long-read single-cell RNA for isoform-level characterization and novel isoforms discovery. 📝 Key Highlights: 🚀 SCOTCH overcomes the limitations of short-read sequencing by employing long-read technologies, enabling thorough analyses of complex genomic regions and precise isoform identification. 🧑‍🔬 Compatible with library preparation platforms from 10X Genomics and Parse Biosciences, and is versatile across diverse cell types such as neurons, hepatocytes, and developing cardiomyocytes. 📈 Differential isoform usage across cell populations, shedding light on cellular functions and disease mechanisms that go beyond traditional gene-level expression analysis. 📚 bioRxiv paper: https://buff.ly/44FsyVx 👨‍💻 GitHub: https://buff.ly/44CEes2 📢 Join the Conversation 📢 Share your ideas, methods, and tools in the comments! 👇 💬 #SingleCellOmics #Transcriptomics #Genomics #Bioinformatics #SCOTCH #BiotechInnovation #PharmaLeaders

21

Avicenna Biosciences, Inc. Enhances ML Tech For Drug Discovery Learn more & get our take 👇 https://lnkd.in/grCZDCHx “Avicenna is applying novel ML methods to navigate the unknowns in medicinal chemistry and design around them. Our methods allow a drug design team to learn from years of failure and optimize against validated targets more efficiently.” – Dr. Thomas Kaiser, Co-founder & CSO at Avicenna Biosciences “Avicenna’s collaborative research with Schrödinger and Microsoft demonstrates how a physics-based augmentation of ML requires just tens of molecules to optimize small molecules against a new drug target, as opposed to thousands.” – Dr. John Hamer, Managing Partner at DCVC Bio #drugdiscovery #machinelearning #SoHCNews

1

🚨 As the new semester kicks off, we’re excited to share our latest NexMR technology developments with those who couldn’t attend this year's conferences. Over the past two years, we’ve made significant progress in advancing NMR technology for drug discovery, including faster and more scalable solutions. Our poster covers: 1) Major innovations in NMR speed and accuracy 2) Proof-of-concept studies on PIN1 protein for ultrafast screening and affinity determination. 3) Seamless integration of light into NMR spectrometers. 4) Implementation of photohyperpolarization to screen fragments with benchtop NMR spectrometers For a closer look at how we’re pushing the boundaries of molecular research, feel free to download our poster in PDF format. If you are attending the qNMR summit (17-19.09.2024) or Drug Discovery 2024 - Elrig (02-03.10.2024), take the chance to reach out and book a 1:1 with our CEO, Félix Torres Hubiche. #nmr #drugdiscovery #biotechnology

27

2 Comments

Happy to share a preprint of our recent work led by Diego Figueroa demonstrating a key role for host CD8 T cell immunity and opposing roles of lymphodepleting preconditioning in the antitumor efficacy of #AdoptiveCellTherapy (ACT). We show that host CD8 T cells contribute to ACT-mediated elimination of primary tumors and rejected ACT-resistant melanoma cells lacking the targeted antigen in mouse models. We also show that lymphodepleting preconditioning enhances expansion of transferred cells and ACT-mediated tumor elimination, but abrogated long-term host antitumor immunity and protection against ACT-resistant melanoma cells. This work highlights the interplay between transferred and endogenous CD8 T cells for the long-term efficacy of ACT, which is undermined by lymphodepleting preconditioning, and may ultimately explain a major mechanism of ACT resistance. Thanks to all the co-authors and collaborators who made this work possible Vincenzo Borgna MD PhD Sofía Hidalgo Triviños Andrés Hernández Oliveras Ximena López Lagos Felipe Galvez-Cancino Fabiola Osorio, PhD Fundación Ciencia & Vida Universidad San Sebastián Vicerrectoría de Investigación y Doctorados USS VRID

65

👏👏Take another look at our #HighlyCitedPaper by Dileep Kumar et al: "Computational and ADMET Predictions of Novel Compounds as Dual Inhibitors of BuChE and GSK-3β to Combat Alzheimer’s Disease" You can find it at: https://lnkd.in/gDxbC2Xx

4